{"id":176299,"date":"2021-03-19T00:00:00","date_gmt":"2021-03-18T23:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/covid-19-pas-de-place-pour-lazithromycine-des-donnees-recentes-le-confirment\/"},"modified":"2026-04-02T19:10:27","modified_gmt":"2026-04-02T17:10:27","slug":"covid-19-pas-de-place-pour-lazithromycine-des-donnees-recentes-le-confirment","status":"publish","type":"post","link":"https:\/\/h.cbip.be\/fr\/covid-19-pas-de-place-pour-lazithromycine-des-donnees-recentes-le-confirment\/","title":{"rendered":"COVID-19: pas de place pour l&rsquo;azithromycine, des donn\u00e9es r\u00e9centes le confirment"},"content":{"rendered":"<p>En raison de ses propri\u00e9t\u00e9s anti-inflammatoires et immunomodulatrices&#x002C; l&#39;azithromycine suscite de l\u2019int\u00e9r\u00eat dans le cadre de la COVID-19. En mai 2020&#x002C; le CBIP concluait que&#x002C; sur la base des donn\u00e9es tr\u00e8s limit\u00e9es disponibles \u00e0 l&#39;\u00e9poque&#x002C; l&#39;azithromycine n\u2019avait pas de place dans le traitement de la COVID-19&#x002C; que ce soit en premi\u00e8re ligne ou \u00e0 l\u2019h\u00f4pital (voir notre communiqu\u00e9 Bon \u00e0 savoir dans les <a href='https:\/\/www.cbip.be\/fr\/articles\/3352?folia=3342'>Folia de mai 2020<\/a>). <strong>Des donn\u00e9es r\u00e9centes viennent le confirmer.<\/strong><\/p>\n<ul>\n<li>\n<p>Dans une <strong>\u00e9tude britannique (PRINCIPLE)&#x002C; \u00e9tude randomis\u00e9e men\u00e9e en premi\u00e8re ligne<\/strong>&#x002C; l&#39;azithromycine n\u2019a \u00e9t\u00e9 associ\u00e9e \u00e0 aucun b\u00e9n\u00e9fice par rapport aux \u00ab\u00a0soins habituels\u00a0\u00bb en ce qui concerne le d\u00e9lai de r\u00e9tablissement ou la n\u00e9cessit\u00e9 d&#39;hospitaliser (crit\u00e8res d&#39;\u00e9valuation primaires) [<a href='https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00461-X\/fulltext'><em>The Lancet<\/em>&#x002C; en ligne le 04\/03\/21<\/a>].<span class='folia-referentie-note'><strong><sup>1<\/sup><\/strong><\/span> L&#39;\u00e9tude portait sur des cas av\u00e9r\u00e9s ou suspect\u00e9s (sur la base des sympt\u00f4mes) de COVID-19 pr\u00e9sentant des facteurs de risque de d\u00e9velopper une forme s\u00e9v\u00e8re de COVID-19.<\/p>\n<\/li>\n<li>\n<p>M\u00eame <strong>en contexte hospitalier<\/strong>&#x002C; l&#39;azithromycine n&#39;a pas de place [voir <a href='https:\/\/covid-19.sciensano.be\/fr\/procedures\/documents-externes'>Sciensano<\/a><em>&#x002C; Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium<\/em> (<a href='https:\/\/covid-19.sciensano.be\/sites\/default\/files\/Covid19\/COVID-19_InterimGuidelines_Treatment_ENG.pdf'>version 09\/03\/21<\/a>)]. Il est fait r\u00e9f\u00e9rence aux <strong>r\u00e9sultats n\u00e9gatifs obtenus avec l&#39;azithromycine dans l&#39;\u00e9tude RECOVERY<\/strong>&#x002C; une \u00e9tude randomis\u00e9e \u00e0 grande \u00e9chelle chez des patients COVID-19 hospitalis\u00e9s&#x002C; dans laquelle divers traitements sont compar\u00e9s aux \u00ab\u00a0soins habituels\u00a0\u00bb [<a href='https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)00149-5\/fulltext'><em>The Lancet<\/em>&#x002C; en ligne le 02\/02\/21<\/a>].<span class='folia-referentie-note'><strong><sup>2<\/sup><\/strong><\/span> Aucun b\u00e9n\u00e9fice n\u2019avait \u00e9t\u00e9 observ\u00e9 avec l&#39;azithromycine (par voie orale ou i.v.) par rapport aux \u00ab\u00a0soins habituels\u00a0\u00bb en ce qui concerne la \u00ab\u00a0mortalit\u00e9 apr\u00e8s 28 jours\u00a0\u00bb (crit\u00e8re d\u2019\u00e9valuation primaire&#x002C; 22% dans les deux groupes) ou la dur\u00e9e d&#39;hospitalisation (10 jours&#x002C; contre 11 jours) ou le crit\u00e8re d\u2019\u00e9valuation combin\u00e9 \u00ab\u00a0ventilation invasive ou d\u00e9c\u00e8s\u00a0\u00bb (crit\u00e8res d\u2019\u00e9valuation secondaires).<\/p>\n<\/li>\n<\/ul>\n<p>\u00a0<br \/> <strong>Note: <\/strong>pour tous nos articles relatifs aux m\u00e9dicaments dans la COVID-19: voir les <a href='https:\/\/www.cbip.be\/fr\/gows\/3334'>Actualit\u00e9s COVID-19 <\/a>\u00a0sur notre site Web.<br \/> \u00a0<\/p>\n<h2>Sources sp\u00e9cifiques<\/h2>\n<div class='reference'><span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>1.\u00a0 <\/span>PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised&#x002C; controlled&#x002C; open-label&#x002C; adaptive platform trial. The Lancet&#x002C; en ligne le 04\/03\/21. Doi: <span class='folia-referentie-link'><a href='https:\/\/doi.org\/10.1016\/S0140-6736(21)00461-X'>https:\/\/doi.org\/10.1016\/S0140-6736(21)00461-X<\/a><\/span><\/span><\/div>\n<div class='reference'><span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>2.\u00a0<\/span> RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised&#x002C; controlled&#x002C; open-label&#x002C; platform trial. The Lancet 2021; 397: 605-12.\u00a0\u00a0 Doi: <span class='folia-referentie-link'><a href='https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5'>https:\/\/doi.org\/10.1016\/S0140-6736(21)00149-5<\/a><\/span><\/span><\/div>\n<p> \u00a0<br \/> \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En raison de ses propri\u00e9t\u00e9s anti-inflammatoires et immunomodulatrices&#x002C; l&#39;azithromycine suscite  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,31],"tags":[48,20213,20224,20226],"class_list":["post-176299","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2021-fr","tag-actualites-covid-19","tag-import_tags","tag-import_tags-nl","tag-covid-19-update"],"_links":{"self":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=176299"}],"version-history":[{"count":1,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176299\/revisions"}],"predecessor-version":[{"id":178878,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/176299\/revisions\/178878"}],"wp:attachment":[{"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=176299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=176299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/h.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=176299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}